Literature DB >> 24422100

Targeted therapies for bone sarcomas.

Dominique Heymann1, Françoise Rédini1.   

Abstract

Bone sarcomas include a very large number of tumour subtypes, which originate form bone and more particularly from mesenchymal stem cell lineage. Osteosarcoma, Ewing's sarcoma and chondrosarcoma, the three main bone sarcoma entities develop in a favourable microenvironment composed by bone cells, blood vessels, immune cells, based on the 'seed and soil theory'. Current therapy associates surgery and chemotherapy, however, bone sarcomas remain diseases with high morbidity and mortality especially in children and adolescents. In the past decade, various new therapeutic approaches emerged and target the tumour niche or/and directly the tumour cells by acting on signalling/metabolic pathways involved in cell proliferation, apoptosis or drug resistance. The present review gives a brief overview from basic to clinical assessment of the main targeted therapies of bone sarcoma cells.

Entities:  

Year:  2013        PMID: 24422100      PMCID: PMC3817966          DOI: 10.1038/bonekey.2013.112

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  90 in total

1.  Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.

Authors:  Katia Scotlandi; Maria Cristina Manara; Massimo Serra; Maria Teresa Marino; Selena Ventura; Cecilia Garofalo; Marco Alberghini; Giovanna Magagnoli; Stefano Ferrari; Jose Antonio Lopez-Guerrero; Antonio Llombard-Bosch; Piero Picci
Journal:  Eur J Cancer       Date:  2011-02-21       Impact factor: 9.162

Review 2.  How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.

Authors:  Dennis P M Hughes
Journal:  Cancer Treat Res       Date:  2009

3.  Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling.

Authors:  Kelai Wang; Yan Zhuang; Chunlan Liu; Yang Li
Journal:  Arch Biochem Biophys       Date:  2012-07-20       Impact factor: 4.013

4.  R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

Authors:  Alberto S Pappo; Shreyaskumar R Patel; John Crowley; Denise K Reinke; Klaus-Peter Kuenkele; Sant P Chawla; Guy C Toner; Robert G Maki; Paul A Meyers; Rashmi Chugh; Kristen N Ganjoo; Scott M Schuetze; Heribert Juergens; Michael G Leahy; Birgit Geoerger; Robert S Benjamin; Lee J Helman; Laurence H Baker
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

5.  Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

Authors:  Heribert Juergens; Najat C Daw; Birgit Geoerger; Stefano Ferrari; Milena Villarroel; Isabelle Aerts; Jeremy Whelan; Uta Dirksen; Mary L Hixon; Donghua Yin; Tao Wang; Stephanie Green; Luisa Paccagnella; Antonio Gualberto
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

6.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

Authors:  G Grignani; E Palmerini; P Dileo; S D Asaftei; L D'Ambrosio; Y Pignochino; M Mercuri; P Picci; F Fagioli; P G Casali; S Ferrari; M Aglietta
Journal:  Ann Oncol       Date:  2011-04-28       Impact factor: 32.976

7.  Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.

Authors:  John M Maris; Joshua Courtright; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Lock; Mayamin Tajbakhsh; C Patrick Reynolds; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

8.  Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells.

Authors:  Frans Van Valen; Simone Fulda; Karl-Ludwig Schäfer; Borna Truckenbrod; Marc Hotfilder; Christopher Poremba; Klaus-Michael Debatin; Winfried Winkelmann
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

9.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

10.  Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Authors:  Ymera Pignochino; Giovanni Grignani; Giuliana Cavalloni; Manuela Motta; Marta Tapparo; Stefania Bruno; Alessia Bottos; Loretta Gammaitoni; Giorgia Migliardi; Giovanni Camussi; Marco Alberghini; Bruno Torchio; Stefano Ferrari; Federico Bussolino; Franca Fagioli; Piero Picci; Massimo Aglietta
Journal:  Mol Cancer       Date:  2009-12-10       Impact factor: 27.401

View more
  13 in total

1.  Chordoma: an update on the pathophysiology and molecular mechanisms.

Authors:  Xin Sun; Francis Hornicek; Joseph H Schwab
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

2.  Description of the immune microenvironment of chondrosarcoma and contribution to progression.

Authors:  François A Simard; Iseulys Richert; Alexandra Vandermoeten; Anne-Valérie Decouvelaere; Jean-Philippe Michot; Christophe Caux; Jean-Yves Blay; Aurélie Dutour
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

3.  Dual modulation of MCL-1 and mTOR determines the response to sunitinib.

Authors:  Mohamed Elgendy; Amal Kamal Abdel-Aziz; Salvatore Lorenzo Renne; Viviana Bornaghi; Giuseppe Procopio; Maurizio Colecchia; Ravindran Kanesvaran; Chee Keong Toh; Daniela Bossi; Isabella Pallavicini; Jose Luis Perez-Gracia; Maria Dolores Lozano; Valeria Giandomenico; Ciro Mercurio; Luisa Lanfrancone; Nicola Fazio; Franco Nole; Bin Tean Teh; Giuseppe Renne; Saverio Minucci
Journal:  J Clin Invest       Date:  2016-11-28       Impact factor: 14.808

4.  Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcoma.

Authors:  Lei Zhao; Ming Lv; Wuliya Sayimu; Wei Liu; Huawu Zhang; B O Jiang; Dong Wang
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

5.  The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors.

Authors:  L He; Z Yang; J Zhou; W Wang
Journal:  Clin Transl Oncol       Date:  2014-11-12       Impact factor: 3.405

Review 6.  Review of Osteosarcoma and Current Management.

Authors:  Ryan A Durfee; Maryam Mohammed; Hue H Luu
Journal:  Rheumatol Ther       Date:  2016-10-19

7.  Delivery of inhibitor of growth 4 (ING4) gene significantly inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells.

Authors:  Mei Li; Ye Zhu; Hongbin Zhang; Lihua Li; Peng He; Hong Xia; Yu Zhang; Chuanbin Mao
Journal:  Sci Rep       Date:  2014-12-09       Impact factor: 4.379

Review 8.  Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers.

Authors:  Aude I Ségaliny; Marta Tellez-Gabriel; Marie-Françoise Heymann; Dominique Heymann
Journal:  J Bone Oncol       Date:  2015-01-23       Impact factor: 4.072

Review 9.  Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.

Authors:  Ander Abarrategi; Juan Tornin; Lucia Martinez-Cruzado; Ashley Hamilton; Enrique Martinez-Campos; Juan P Rodrigo; M Victoria González; Nicola Baldini; Javier Garcia-Castro; Rene Rodriguez
Journal:  Stem Cells Int       Date:  2016-06-05       Impact factor: 5.443

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.